Before they began their summer vacations, three biotechnology companies raised $62m in venture capital financing and three drug developers grossed $232m in initial public offerings.
Before they began their summer vacations, three biotechnology companies raised $62m in venture capital financing and three drug developers grossed $232m in initial public offerings.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The end of semaglutide and tirzepatide shortages means large-scale compounding is declining, ICER noted. But compounded versions – and the demand for them – are likely here to stay.
Adstiladrin sales hit €70m in first full year on the market
ICER’s new white paper pointed to estimates that the GLP-1 drugs may result in more than $100bn in annual spending, highlighting the need to rein in costs.
The company plans a tiered sales approach as it targets endocrinologists for hypothalamic obesity, which is more widely diagnosed than its current indication for Bardet-Biedl syndrome.
Adstiladrin sales hit €70m in first full year on the market
ICER’s new white paper pointed to estimates that the GLP-1 drugs may result in more than $100bn in annual spending, highlighting the need to rein in costs.
The company announced positive Phase IIb data for Descartes-08 in myasthenia gravis, with especially strong efficacy among patients without prior biologic treatment.
